Search

Your search keyword '"C. Naclerio"' showing total 7 results
Start Over Author "C. Naclerio" Topic scleroderma, systemic
7 results on '"C. Naclerio"'

1. Assessment of intestinal permeability and orocecal transit time in patients with systemic sclerosis: analysis of relationships with epidemiologic and clinical parameters.

Author

Caserta L, de Magistris L, Secondulfo M, Caravelli G, Riegler G, Cuomo G, D'Angelo S, Naclerio C, Valentini G, and Carratù R

Subjects
Adult, Aged, Autoantibodies immunology, Breath Tests, Case-Control Studies, DNA Topoisomerases, Type I, Diagnostic Techniques, Digestive System, Female, Gastrointestinal Transit immunology, Humans, Intestinal Mucosa metabolism, Intestines immunology, Male, Middle Aged, Nuclear Proteins immunology, Permeability, Scleroderma, Systemic immunology, Severity of Illness Index, Gastrointestinal Transit physiology, Intestines physiology, Scleroderma, Systemic physiopathology
Abstract

Objective: The aim of this study was to assess intestinal permeability (IP) in patients with systemic sclerosis (SSc) and to relate the results with general disease activity and gastrointestinal involvement., Methods: Twenty-eight females and four males were studied. Patients with severe gastrointestinal involvement were excluded. Thirty-three healthy volunteers served as controls. Intestinal permeability was assessed by means of the orally administered cellobiose/mannitol sugar (Ce/Ma) test. Intestinal transit time (ITT) was investigated with the H2-lactulose breath test., Results: The mean value of IP in 32 SSc patients was significantly higher than in 33 controls ( P<0.05), although it fell within the normal range. Eleven patients showed abnormally high individual IP values (>0.028) that significantly correlated to disease duration ( r=0.73). Altered IP was associated with the higher but not statistically relevant presence of anti-Scl70 antibodies (9/11) and to more severe gastrointestinal involvement. More than half of the SSc patients showed slower orocecal transit times on the H2 breath test. In particular, delayed ITT was observed in 60% of patients with increased IP and in all patients with moderate gastrointestinal involvement according to the scleroderma severity scale., Conclusion: Intestinal permeability was altered in 11/32 SSc patients. Correlations between increased IP and duration of disease and degree of gastrointestinal involvement appear to support the hypothesis of secondary involvement of the intestinal barrier, and the presence of anti-Scl70 antibodies in 82% of the patients with higher IP clearly reinforces the hypothesis of an altered immune response in these subjects.

Published
2003
Full Text
View/download PDF

2. Cardiac autonomic dysfunction precedes the development of fibrosis in patients with systemic sclerosis.

Author

Cozzolino D, Naclerio C, Iengo R, D'Angelo S, Cuomo G, and Valentini G

Subjects
Adolescent, Adult, Autonomic Nervous System Diseases physiopathology, Diagnostic Techniques, Cardiovascular, Female, Fibrosis physiopathology, Humans, Scleroderma, Systemic physiopathology, Autonomic Nervous System Diseases etiology, Fibrosis complications, Scleroderma, Systemic complications
Published
2002
Full Text
View/download PDF

3. Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation.

Author

Valentini G, Baroni A, Esposito K, Naclerio C, Buommino E, Farzati A, Cuomo G, and Farzati B

Subjects
Adult, Case-Control Studies, Female, Humans, In Vitro Techniques, Interferon-gamma genetics, Interferon-gamma metabolism, Interleukin-2 genetics, Interleukin-2 metabolism, Interleukin-4 genetics, Interleukin-4 metabolism, Lymphocyte Activation drug effects, Male, Middle Aged, RNA, Messenger genetics, RNA, Messenger metabolism, Scleroderma, Systemic genetics, Tetradecanoylphorbol Acetate pharmacology, Th1 Cells drug effects, Th2 Cells drug effects, Scleroderma, Systemic immunology, Th1 Cells immunology, Th2 Cells immunology
Abstract

Our objective was to investigate the phenotype of helper T cells in the peripheral blood of patients with systemic sclerosis (SSc). PBMC from 15 patients with SSc and 15 sex- and age-matched controls were investigated for lymphocyte subpopulations (CD3, CD4, CD8, CD19, CD16/CD56, CD3-DR); IL-2, IL-4, and IFN-gamma mRNAs; and the relative cytokines in their cytoplasm. The last assay was carried out both in unstimulated and in PMA-activated PBMC. SSc patients presented a higher percentage of activated T cells, CD3+ DR+ (19.7 +/- 9.9 vs 5.1 +/- 2.5%; P < 0.0001); 12 of them presented IFN-gamma mRNA-positive cells; and none IL-2 or IL-4 mRNAs. Under basal conditions, PBMC from six SSc patients contained IL-2, IL-4, and IFN-gamma (i.e., they showed both Th1 and Th2 activation), and 1 IFN-gamma only. PMA-stimulated PBMC of patients differed from those of controls only in the increased percentage of IFN-gamma positive cells (52 +/- 12 vs 37 +/- 11%; P < 0.01). Our study demonstrates that Thl activation occurs in the peripheral blood of SSc patients. This evidence must be faced with from both a pathogenetic and a therapeutical point of view.

Published
2001
Full Text
View/download PDF

4. Increased expression of CD40 ligand in activated CD4+ T lymphocytes of systemic sclerosis patients.

Author

Valentini G, Romano MF, Naclerio C, Bisogni R, Lamberti A, Turco MC, and Venuta S

Subjects
Adult, Antibodies, Blocking pharmacology, CD4-Positive T-Lymphocytes immunology, CD40 Ligand, Female, Humans, Ligands, Male, Membrane Glycoproteins physiology, Middle Aged, Muromonab-CD3 pharmacology, Scleroderma, Systemic etiology, CD4-Positive T-Lymphocytes metabolism, CD40 Antigens metabolism, Lymphocyte Activation, Membrane Glycoproteins biosynthesis, Scleroderma, Systemic immunology
Abstract

CD40-CD154 interactions play a key role in regulating immune response and are involved in the development of some autoimmune diseases. We analysed the expression of CD154 antigen in CD3-activated PBMC from 10 systemic sclerosis (SSc) patients and 10 control subjects by immunofluorescence. PBMC from SSc patients showed an increased expression of this molecule, since, 6 h following CD3 stimulation, the percentage of CD154(+)cells was of 17. 53+/-2.0 (mean+/-SE) in control and 25.33+/-2.93 in patient cells (P< 0.03). The higher expression of CD154 antigen was ascribible to CD4(+)cells. The enhanced induction of CD154 following CD3 stimulation depended on protein synthesis, since was abolished when the cells were stimulated via CD3 in the presence of cycloheximide. By analysing the expression of the CD40-induced antigen CD80, we verified that a blocking anti-CD40 antibody inhibited CD80 appearance in SSc activated monocytes, indicating that CD154 molecule was functional. These results show an enhanced expression of a functional CD154 molecule in SSc CD4(+)activated T lymphocytes., (Copyright 2000 Academic Press.)

Published
2000
Full Text
View/download PDF

5. Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups

Author

Domenico Olivo, E. Pigatto, Francesca La Gualana, Giorgio Amato, Ilaria Cavazzana, Rosario Foti, Antonio Tavoni, Raffaele Brittelli, Tommaso Ferrari, Francesco Masini, Marcella Visentini, Stefano Angelo Santini, Dilia Giuggioli, Franco Franceschini, Vincenzo Raimondo, Laura Gragnani, Giuseppa Pagano Mariano, Poupak Fallahi, Vincenzo Aiello, Lorenzo Puccetti, C. Naclerio, Riccardo Meliconi, Giovanna Cuomo, Amelia Spinella, Ylenia Dal Bosco, Alessandro Antonelli, Daniela Scorpiniti, M. Vadacca, Piero Ruscitti, Milvia Casato, Elisa Visalli, Florenzo Iannone, Maurizio Caminiti, Fabio Cacciapaglia, Francesco Ursini, Clodoveo Ferri, T. Urraro, Rodolfo Caminiti, Monica Monti, Massimo L'Andolina, Giovanni Rechichi, Anna Linda Zignego, Roberto Giacomelli, Giuseppe Varcasia, Roberta Pellegrini, Franco Cozzi, Pietro Gigliotti, Giusy Elia, Ferri, C., Ursini, F., Gragnani, L., Raimondo, V., Giuggioli, D., Foti, R., Caminiti, M., Olivo, D., Cuomo, G., Visentini, M., Cacciapaglia, F., Pellegrini, R., Pigatto, E., Urraro, T., Naclerio, C., Tavoni, A., Puccetti, L., Varcasia, G., Cavazzana, I., L'Andolina, M., Ruscitti, P., Vadacca, M., Gigliotti, P., La Gualana, F., Cozzi, F., Spinella, A., Visalli, E., Dal Bosco, Y., Amato, G., Masini, F., Pagano Mariano, G., Brittelli, R., Aiello, V., Caminiti, R., Scorpiniti, D., Rechichi, G., Ferrari, T., Monti, M., Elia, G., Franceschini, F., Meliconi, R., Casato, M., Iannone, F., Giacomelli, R., Fallahi, P., Santini, S. A., Zignego, A. L., Antonelli, A., Ferri C., Ursini F., Gragnani L., Raimondo V., Giuggioli D., Foti R., Caminiti M., Olivo D., Cuomo G., Visentini M., Cacciapaglia F., Pellegrini R., Pigatto E., Urraro T., Naclerio C., Tavoni A., Puccetti L., Varcasia G., Cavazzana I., L'Andolina M., Ruscitti P., Vadacca M., Gigliotti P., La Gualana F., Cozzi F., Spinella A., Visalli E., Dal Bosco Y., Amato G., Masini F., Pagano Mariano G., Brittelli R., Aiello V., Caminiti R., Scorpiniti D., Rechichi G., Ferrari T., Monti M., Elia G., Franceschini F., Meliconi R., Casato M., Iannone F., Giacomelli R., Fallahi P., Santini S.A., Zignego A.L., and Antonelli A.

Subjects
Male, History, Polymers and Plastics, Binding Antibody Units, BAU, Antibodies, Viral, Gastroenterology, Industrial and Manufacturing Engineering, Cryoglobulinemic vasculitis, CV, Scleroderma, Systemic sclerosi, Systemic lupu, Anti-citrullinated protein antibodies, ACPA, Systemic vasculitis, Lupus Erythematosus, Systemic, Immunology and Allergy, Medicine, Viral, Prospective Studies, Prospective cohort study, Neutralizing, education.field_of_study, Autoimmune systemic diseases, COVID-19 vaccine, Cryoglobulinemic vasculitis, Neutralizing antibodies, Rheumatoid arthritis, Systemic lupus, Systemic sclerosis, Immunogenicity, Vaccination, Middle Aged, Neutralizing antibody, NAb, Rheumatoid factor, RF, Italy, Female, Rituximab, Systemic sclerosis, SSc, Adverse events, AEs, 2019-nCoV Vaccine mRNA-1273, Human, medicine.drug, medicine.medical_specialty, Systemic lupus erythematosus, SLE, Immunology, Population, Autoimmune systemic disease, Autoimmune Disease, Article, Antibodies, Autoimmune Diseases, Internal medicine, Neutralizing antibodie, Humans, Business and International Management, Seroconversion, education, Settore BIO/10 - BIOCHIMICA, Vaccine Potency, Rheumatoid arthriti, BNT162 Vaccine, Scleroderma, Systemic, Lupus Erythematosus, Cryoglobulinemic vasculiti, SARS-CoV-2, business.industry, Systemic, Systemic Vasculiti, COVID-19, medicine.disease, Antibodies, Neutralizing, Autoimmune systemic diseases, ASD, Prospective Studie, World Health Organization, WHO, Rheumatoid arthritis, RA, Systemic Vasculitis, business
Abstract

Autoimmune systemic diseases (ASD) may show impaired immunogenicity to COVID-19 vaccines. Our prospective observational multicenter study aimed to evaluate the seroconversion after the vaccination cycle and at 6-12-month follow-up, as well the safety and efficacy of vaccines in preventing COVID-19. The study included 478 unselected ASD patients (mean age 59 ± 15 years), namely 101 rheumatoid arthritis (RA), 38 systemic lupus erythematosus (SLE), 265 systemic sclerosis (SSc), 61 cryoglobulinemic vasculitis (CV), and a miscellanea of 13 systemic vasculitis. The control group included 502 individuals from the general population (mean age 59 ± 14SD years). The immunogenicity of mRNA COVID-19 vaccines (BNT162b2 and mRNA-1273) was evaluated by measuring serum IgG-neutralizing antibody (NAb) (SARS-CoV-2 IgG II Quant antibody test kit; Abbott Laboratories, Chicago, IL) on samples obtained within 3 weeks after vaccination cycle. The short-term results of our prospective study revealed significantly lower NAb levels in ASD series compared to controls [286 (53–1203) vs 825 (451–1542) BAU/mL, p < 0.0001], as well as between single ASD subgroups and controls. More interestingly, higher percentage of non-responders to vaccine was recorded in ASD patients compared to controls [13.2% (63/478), vs 2.8% (14/502); p < 0.0001]. Increased prevalence of non-response to vaccine was also observed in different ASD subgroups, in patients with ASD-related interstitial lung disease (p = 0.009), and in those treated with glucocorticoids (p = 0.002), mycophenolate-mofetil (p < 0.0001), or rituximab (p < 0.0001). Comparable percentages of vaccine-related adverse effects were recorded among responder and non-responder ASD patients. Patients with weak/absent seroconversion, believed to be immune to SARS-CoV-2 infection, are at high risk to develop COVID-19. Early determination of serum NAb after vaccination cycle may allow to identify three main groups of ASD patients: responders, subjects with suboptimal response, non-responders. Patients with suboptimal response should be prioritized for a booster-dose of vaccine, while a different type of vaccine could be administered to non-responder individuals.

Published
2022

6. Assessment of intestinal permeability and orocecal transit time in patients with systemic sclerosis: analysis of relationships with epidemiologic and clinical parameters

Author

Mario Secondulfo, G. Caravelli, L. Caserta, C. Naclerio, Giovanna Cuomo, Gabriele Valentini, Salvatore D'Angelo, Gabriele Riegler, Laura de Magistris, and Romano Carratù

Subjects
Adult, Male, medicine.medical_specialty, Systemic disease, Immunology, Gastroenterology, Severity of Illness Index, Permeability, Rheumatology, Internal medicine, Immunopathology, Severity of illness, Epidemiology, medicine, Immunology and Allergy, Humans, Intestinal Mucosa, skin and connective tissue diseases, Gastrointestinal Transit, Aged, Autoantibodies, Intestinal permeability, Scleroderma, Systemic, integumentary system, business.industry, Case-control study, Nuclear Proteins, Middle Aged, medicine.disease, Connective tissue disease, Intestines, Diagnostic Techniques, Digestive System, Breath Tests, DNA Topoisomerases, Type I, Case-Control Studies, Female, business
Abstract

The aim of this study was to assess intestinal permeability (IP) in patients with systemic sclerosis (SSc) and to relate the results with general disease activity and gastrointestinal involvement.Twenty-eight females and four males were studied. Patients with severe gastrointestinal involvement were excluded. Thirty-three healthy volunteers served as controls. Intestinal permeability was assessed by means of the orally administered cellobiose/mannitol sugar (Ce/Ma) test. Intestinal transit time (ITT) was investigated with the H2-lactulose breath test.The mean value of IP in 32 SSc patients was significantly higher than in 33 controls ( P0.05), although it fell within the normal range. Eleven patients showed abnormally high individual IP values (0.028) that significantly correlated to disease duration ( r=0.73). Altered IP was associated with the higher but not statistically relevant presence of anti-Scl70 antibodies (9/11) and to more severe gastrointestinal involvement. More than half of the SSc patients showed slower orocecal transit times on the H2 breath test. In particular, delayed ITT was observed in 60% of patients with increased IP and in all patients with moderate gastrointestinal involvement according to the scleroderma severity scale.Intestinal permeability was altered in 11/32 SSc patients. Correlations between increased IP and duration of disease and degree of gastrointestinal involvement appear to support the hypothesis of secondary involvement of the intestinal barrier, and the presence of anti-Scl70 antibodies in 82% of the patients with higher IP clearly reinforces the hypothesis of an altered immune response in these subjects.

Published
2002

7. Increased expression of CD40 ligand in activated CD4+ T lymphocytes of systemic sclerosis patients

Author

Maria Romano, Salvatore Venuta, Rita Bisogni, Annalisa Lamberti, C. Naclerio, Maria Caterina Turco, Gabriele Valentini, Valentini, Gabriele, Romano, Mf, Naclerio, C, Bisogni, R, Lamberti, A, Turco, Mc, and Venuta, S.

Subjects
Adult, CD4-Positive T-Lymphocytes, Male, CD154, systemic sclerosis, T lymphocytes, CD3, Immunology, CD40 Ligand, chemical and pharmacologic phenomena, Ligands, Lymphocyte Activation, Immune system, Antigen, Immunology and Allergy, Humans, CD154, CD40 Antigens, Antibodies, Blocking, CD40, Membrane Glycoproteins, Scleroderma, Systemic, biology, hemic and immune systems, T lymphocyte, Middle Aged, Molecular biology, biology.protein, Female, Antibody, CD80, Muromonab-CD3
Abstract

CD40-CD154 interactions play a key role in regulating immune response and are involved in the development of some autoimmune diseases. We analysed the expression of CD154 antigen in CD3-activated PBMC from 10 systemic sclerosis (SSc) patients and 10 control subjects by immunofluorescence. PBMC from SSc patients showed an increased expression of this molecule, since, 6 h following CD3 stimulation, the percentage of CD154(+)cells was of 17. 53+/-2.0 (mean+/-SE) in control and 25.33+/-2.93 in patient cells (P0.03). The higher expression of CD154 antigen was ascribible to CD4(+)cells. The enhanced induction of CD154 following CD3 stimulation depended on protein synthesis, since was abolished when the cells were stimulated via CD3 in the presence of cycloheximide. By analysing the expression of the CD40-induced antigen CD80, we verified that a blocking anti-CD40 antibody inhibited CD80 appearance in SSc activated monocytes, indicating that CD154 molecule was functional. These results show an enhanced expression of a functional CD154 molecule in SSc CD4(+)activated T lymphocytes.

Published
2000

Catalog

Books, media, physical & digital resources
See catalog results